Solana, Elisabeth
Martinez-Heras, Eloy
Casas-Roma, Jordi
Calvet, Laura
Lopez-Soley, Elisabet
Sepulveda, Maria
Sola-Valls, Nuria
Montejo, Carmen
Blanco, Yolanda
Pulido-Valdeolivas, Irene
Andorra, Magi
Saiz, Albert
Prados, Ferran
Llufriu, Sara
Article History
Received: 17 September 2019
Accepted: 25 November 2019
First Online: 27 December 2019
Competing interests
: E.S., E.M.H., J.C.R., L.C., E.L.S., C.M., M.A. and F.P. have nothing to disclose. M.S. received speaker honoraria from Genzyme, Novartis and Biogen; N.S. received compensation for consulting services and speaker honoraria from Genzyme-Sanofi and Bayer-Schering; Y.B. received speaking honoraria from Biogen, Novartis and Genzyme; I.P.V. holds a patent for an affordable eye tracking system to measure eye movement in neurologic diseases and holds stock options in Aura Innovative Robotics; A.S. received compensation for consulting services and speaker honoraria from Bayer-Schering, Merck-Serono, Biogen-Idec, Sanofi-Aventis, TEVA, Novartis and Roche; S.L. received compensation for consulting services and speaker honoraria from Biogen Idec, Novartis, TEVA, Genzyme, Sanofi and Merck.